Related Experiment Video
Updated: Oct 12, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
The Preliminary Study on the Proapoptotic Effect of Reduced Graphene Oxide in Breast Cancer Cell Lines
Rafał Krętowski1, Agata Jabłońska-Trypuć2, Marzanna Cechowska-Pasko1
1Department of Pharmaceutical Biochemistry, Medical University of Bialystok, 15-089 Bialystok, Poland.
Abstract:
Breast cancer is the most common cancer diagnosed in women, however traditional therapies have several side effects. This has led to an urgent need to explore novel drug approaches to treatment strategies such as graphene-based nanomaterials such as reduced graphene oxide (rGO). It was noticed as a potential drug due to its target selectivity, easy functionalisation, chemisensitisation, and high drug-loading capacity. rGO is widely used in many fields, including biological and biomedical, due to its unique physicochemical properties. However, the possible mechanisms of rGO toxicity remain unclear. In this paper, we present findings on the cytotoxic and antiproliferative effects of rGO and its ability to induce oxidative stress and apoptosis of breast cancer cell lines. We indicate that rGO induced time- and dose-dependent cytotoxicity in MDA-MB-231 and ZR-75-1 cell lines, but not in T-47D, MCF-7, Hs 578T cell lines. In rGO-treated MDA-MB-231 and ZR-75-1 cell lines, we noticed increased induction of apoptosis and necrosis. In addition, rGO has been found to cause oxidative stress, reduce proliferation, and induce structural changes in breast cancer cells. Taken together, these studies provide new insight into the mechanism of oxidative stress and apoptosis in breast cancer cells.
Insights
Reduced graphene oxide (rGO) shows promise as a novel breast cancer therapy, inducing cell death and oxidative stress in specific cancer lines. Further research is needed to clarify its mechanisms and potential applications.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Breast cancer is a leading cause of death in women, with existing therapies causing significant side effects.
- Novel therapeutic strategies are urgently needed, and graphene-based nanomaterials like reduced graphene oxide (rGO) show potential.
- rGO's unique properties, including target selectivity and drug-loading capacity, make it a candidate for cancer treatment.
Purpose of the Study:
- To investigate the cytotoxic and antiproliferative effects of reduced graphene oxide (rGO) on breast cancer cell lines.
- To explore the mechanisms by which rGO affects cancer cells, specifically focusing on oxidative stress and apoptosis.
- To determine the differential effects of rGO on various breast cancer subtypes.
Main Methods:
- Treatment of distinct breast cancer cell lines (MDA-MB-231, ZR-75-1, T-47D, MCF-7, Hs 578T) with varying concentrations and durations of rGO.
- Assessment of cytotoxicity and antiproliferative activity using cell viability assays.
- Evaluation of oxidative stress induction through relevant biomarkers.
- Analysis of apoptosis and necrosis using flow cytometry and other assays.
- Microscopic examination of cellular structural changes.
Main Results:
- rGO demonstrated time- and dose-dependent cytotoxicity in MDA-MB-231 and ZR-75-1 cell lines.
- No significant cytotoxicity was observed in T-47D, MCF-7, and Hs 578T cell lines.
- rGO treatment led to increased apoptosis and necrosis in sensitive cell lines (MDA-MB-231, ZR-75-1).
- Oxidative stress was induced, proliferation was reduced, and structural changes were observed in treated breast cancer cells.
Conclusions:
- Reduced graphene oxide exhibits selective cytotoxicity against certain breast cancer cell lines.
- rGO induces oxidative stress and apoptosis, contributing to its antiproliferative effects.
- These findings provide insights into the potential therapeutic mechanisms of rGO in breast cancer treatment.
